Clinical Trial Update: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial of beloranib (ZGN-440) in obese individuals with Prader-Willi syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Prader-willi Syndrome

Drugs mentioned

• Beloranib (ZGN-440) (Beloranib)

Snippet

Sponsor: Zafgen, Inc. | Conditions: Prader-Willi Syndrome, Obesity | Phase 3 | Status: TERMINATED